CPT® Code 84410

Official Description

Testosterone; bioavailable, direct measurement (eg, differential precipitation)

Common Language Description

The CPT® Code 84410 refers to a laboratory test specifically designed to measure bioavailable testosterone in serum. Testosterone is classified as an androgen hormone, which is produced by both males and females. In the bloodstream, the majority of testosterone is bound to a protein known as sex hormone binding globulin (SHBG), rendering it biologically inactive. However, testosterone that is free or bound to albumin is considered active and bioavailable, meaning it can exert physiological effects in the body. This test is particularly useful in diagnosing androgen deficiency in males, especially when total testosterone levels are at the lower limits of normal. Additionally, it can help identify alterations in SHBG levels that may occur due to factors such as aging, obesity, or the use of certain medications. In females, the test is valuable for diagnosing conditions associated with hyperandrogenism, including amenorrhea, hirsutism, polycystic ovarian syndrome (PCOS), and virilization. The procedure involves obtaining a blood sample through venipuncture, which is separately reportable. The measurement of serum concentration of free testosterone is achieved through a method known as differential precipitation, which involves the use of SHBG and ammonium sulfate after the serum specimen has been equilibrated with tracer amounts of tritium-labeled testosterone.

1. Indications

The CPT® Code 84410 is indicated for use in various clinical scenarios where the measurement of bioavailable testosterone is necessary. The following conditions and symptoms may warrant this laboratory test:

Androgen Deficiency in Males This test is performed when total testosterone levels are at the lower limits of normal, helping to confirm a diagnosis of androgen deficiency.
Alteration of SHBG The test may be indicated for suspected changes in SHBG levels due to factors such as aging, obesity, or the ingestion of certain medications.
Hyperandrogenism in Women The test is useful for diagnosing hyperandrogenism in females who present with symptoms such as amenorrhea, hirsutism, polycystic ovarian syndrome (PCOS), and/or virilization.

2. Procedure

The procedure for obtaining the results associated with CPT® Code 84410 involves several key steps that ensure accurate measurement of bioavailable testosterone. The following procedural steps are outlined:

Step 1: Blood Sample Collection A blood sample is obtained from the patient through a process known as venipuncture. This step is crucial as it provides the serum needed for the subsequent analysis. The venipuncture must be performed by a qualified healthcare professional to ensure proper technique and minimize discomfort for the patient.
Step 2: Serum Preparation Once the blood sample is collected, it is processed to separate the serum from the cellular components. This involves centrifugation, which allows for the clear serum to be isolated for testing.
Step 3: Differential Precipitation The serum is then subjected to differential precipitation, a method that utilizes SHBG and ammonium sulfate. This process helps to isolate the free testosterone from the bound forms, allowing for an accurate measurement of the bioavailable testosterone levels.
Step 4: Measurement Following the differential precipitation, the concentration of free testosterone is measured using tracer amounts of tritium-labeled testosterone. This step is essential for quantifying the bioavailable testosterone in the serum sample.

3. Post-Procedure

After the procedure associated with CPT® Code 84410, the patient may be advised on any necessary post-venipuncture care, such as applying pressure to the site to prevent bleeding and keeping the area clean. The results of the test will typically be analyzed and reported back to the healthcare provider, who will interpret the findings in the context of the patient's clinical presentation. It is important for the provider to consider the results alongside other diagnostic information to make informed decisions regarding further evaluation or treatment options. No specific recovery time is required for the patient following this laboratory test, as it is a minimally invasive procedure.

Short Descr	TESTOSTERONE BIOAVAILABLE
Medium Descr	ASSAY BIOVLBL TESTOSTERONE DIRECT MEASUREMENT
Long Descr	Testosterone; bioavailable, direct measurement (eg, differential precipitation)
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GA	Waiver of liability statement issued as required by payer policy, individual case
59	Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
GW	Service not related to the hospice patient's terminal condition